🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

Kwality Pharmaceuticals Limited KPL NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.kwalitypharma.com
Company Profile ↓
₹3,618.30
+117.63% 1Y
P/E46.33
P/B11.15
52W High₹3,844.90
52W Low₹1,579.55
Book Value₹319.57
EPS (TTM)₹78.10

Company Overview

Kwality Pharmaceuticals Limited, together with its subsidiary, manufactures finished pharmaceutical formulations in India and internationally. The company offers its products in various dosage forms, including capsules, eye and ear drops, ointments and creams, pouches and sachets, sanitizers, tablets, suppositories, injectable vials and ampoules, liquid orals, lyophilized products, syrups, and various other categories, such as general, beta-lactam, cephalosporins, oncology, biologics, and hormones and specialty injectables. It also provides intermediates, chemicals, extracts, alkaloids, toilet requisites, beverages, and other medical preparations. Kwality Pharmaceuticals Limited was incorporated in 1983 and is based in Amritsar, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 20.2%, reflecting efficient use of shareholder capital.

Consistent Profit Growth

Net profit has compounded at 46.6% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 22.9% CAGR over the past five years.

Healthy Margins

Operating margin of 22.6% supports profitability.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.40.

Recent Developments

  • Mar 2026 Revenue of ₹503.00 Cr (+35.9% YoY); net profit ₹67.00 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +45.6%, earnings +114.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR 22.9%, profit CAGR 46.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:22.91%
1 Year:45.60%

Compounded Profit Growth

5 Years:46.56%
1 Year:114.90%

Stock Price Performance

1 Year:+117.63%
6 Months:+120.39%
3 Months:+35.40%
1 Month:-5.89%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot
52-Week Range 90% of range
₹1,579.55 ₹3,844.90
Trend Signals
  • Price vs 50-DMAAbove
  • RSI (14)55.23 · Neutral
Price Performance
1M-5.89%
3M+35.40%
6M+120.39%
1Y+117.63%
Valuation vs Sector

P/E of 46.33 is above the sector median of 35.90 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 20.2%.
  • Compounding revenue at 22.9% over 5 years.
  • Profit CAGR of 46.6% over 5 years.

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
46.33
Industry PE
35.90
Forward P/E est.
23.16
PEG Ratio
-
Book Value
₹319.57
Price to Book
11.15
P/S
-
EV/EBITDA
27.57
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
22.91%
Profit 5Y
46.56%
Revenue (YoY)
45.60%
Earnings (YoY)
114.90%

Profitability & Returns

ROCE
-
ROE
20.24%
ROA
11.32%
Profit Margin
14.63%
Op Margin
22.57%
Gross Margin
46.68%
EPS (Latest Qtr)
₹24.38
EPS (TTM)
₹78.10

Balance Sheet & Liquidity

Debt/Equity
0.40
Quick Ratio
1.30
Current Ratio
1.80
Debt
₹130.71 Cr
Total Assets
₹592.00 Cr
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
77.49%
Chg in Prom Hold
-1.06%
FII / Inst Holding
0.00%
Chg in FII Hold
-3.15%

Financial Snapshot

Enterprise Value
₹3,791.66 Cr
Total Revenue (TTM)
₹553.96 Cr
EBITDA
₹137.50 Cr
Free Cash Flow
₹-29.00 Cr
Operating Cash Flow
₹17.00 Cr
Shares Outstanding
-
Gross Margin
46.68%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 KPL Kwality Pharmaceuticals Limited NSEPHARMA 3,618.30 46.33 - 0.00% - 20.24% 22.91% 46.56%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,758.00 34.88 ₹4.22 L Cr 0.91% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,162.00 83.32 ₹2.43 L Cr 0.32% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,615.30 73.73 ₹1.76 L Cr 0.81% 9.05% 25.79% 13.27% 20.22%
5 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,135.00 25.30 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 634.25 165.17 ₹1.10 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 7,604.50 52.35 ₹1.09 L Cr 0.25% 19.20% 20.48% 14.85% 33.34%
8 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 2,002.50 98.99 ₹1.08 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
9 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,330.90 31.92 ₹1.08 L Cr 0.99% 14.86% 11.27% 7.23% 11.45%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 69.00 Cr67.00 Cr70.00 Cr78.00 Cr92.00 Cr80.00 Cr90.00 Cr84.00 Cr116.00 Cr111.00 Cr111.00 Cr123.00 Cr157.00 Cr
Operating Expenses 57.00 Cr54.00 Cr54.00 Cr61.00 Cr71.00 Cr63.00 Cr70.00 Cr67.00 Cr90.00 Cr87.00 Cr86.00 Cr93.00 Cr118.00 Cr
Operating Income 7.00 Cr9.00 Cr10.00 Cr12.00 Cr16.00 Cr13.00 Cr15.00 Cr13.00 Cr21.00 Cr19.00 Cr20.00 Cr25.00 Cr34.00 Cr
EBITDA 11.00 Cr14.00 Cr15.00 Cr17.00 Cr21.00 Cr17.00 Cr20.00 Cr18.00 Cr26.00 Cr24.00 Cr25.00 Cr30.00 Cr39.00 Cr
Interest Expense 2.00 Cr2.00 Cr2.00 Cr3.00 Cr3.00 Cr2.00 Cr3.00 Cr2.00 Cr2.00 Cr3.00 Cr3.00 Cr2.00 Cr3.00 Cr
Pretax Income -10.00 Cr7.00 Cr8.00 Cr10.00 Cr6.00 Cr11.00 Cr13.00 Cr11.00 Cr19.00 Cr17.00 Cr18.00 Cr22.00 Cr32.00 Cr
Tax Provision 2.40 Cr1.75 Cr1.92 Cr2.10 Cr1.74 Cr2.75 Cr4.29 Cr2.75 Cr4.56 Cr5.10 Cr4.14 Cr6.16 Cr6.40 Cr
Net Income -7.00 Cr5.00 Cr6.00 Cr8.00 Cr4.00 Cr8.00 Cr8.00 Cr9.00 Cr14.00 Cr12.00 Cr14.00 Cr16.00 Cr25.00 Cr
Diluted EPS -7.115.226.017.414.208.068.168.2213.9611.5013.6115.4324.38

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 52.00 Cr74.00 Cr98.00 Cr137.00 Cr166.00 Cr139.00 Cr262.00 Cr456.00 Cr251.00 Cr307.00 Cr370.00 Cr503.00 Cr
Operating Expenses 49.00 Cr69.00 Cr89.00 Cr126.00 Cr150.00 Cr125.00 Cr233.00 Cr285.00 Cr190.00 Cr241.00 Cr290.00 Cr385.00 Cr
Operating Income 2.00 Cr3.00 Cr6.00 Cr9.00 Cr13.00 Cr10.00 Cr23.00 Cr161.00 Cr46.00 Cr46.00 Cr62.00 Cr98.00 Cr
EBITDA 3.00 Cr5.00 Cr9.00 Cr12.00 Cr16.00 Cr14.00 Cr29.00 Cr172.00 Cr61.00 Cr66.00 Cr80.00 Cr118.00 Cr
Interest Expense 1.00 Cr1.00 Cr2.00 Cr2.00 Cr2.00 Cr3.00 Cr3.00 Cr3.00 Cr7.00 Cr10.00 Cr10.00 Cr11.00 Cr
Pretax Income 1.00 Cr2.00 Cr6.00 Cr7.00 Cr11.00 Cr11.00 Cr21.00 Cr162.00 Cr26.00 Cr31.00 Cr54.00 Cr89.00 Cr
Tax Provision 41.00 L96.00 L2.52 Cr2.73 Cr3.41 Cr2.75 Cr6.30 Cr42.12 Cr6.50 Cr7.44 Cr14.04 Cr22.25 Cr
Net Income 1.00 Cr1.00 Cr3.00 Cr4.00 Cr8.00 Cr8.00 Cr15.00 Cr120.00 Cr19.00 Cr24.00 Cr40.00 Cr67.00 Cr
Diluted EPS 0.921.553.234.397.288.0214.60115.6418.6722.9438.4164.91

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 37.00 Cr51.00 Cr71.00 Cr96.00 Cr105.00 Cr133.00 Cr166.00 Cr341.00 Cr361.00 Cr394.00 Cr447.00 Cr592.00 Cr
Total Equity 19.00 Cr22.00 Cr25.00 Cr29.00 Cr37.00 Cr46.00 Cr61.00 Cr181.00 Cr200.00 Cr224.00 Cr264.00 Cr331.00 Cr
Total Debt 8.00 Cr13.00 Cr19.00 Cr26.00 Cr29.00 Cr35.00 Cr41.00 Cr54.00 Cr90.00 Cr98.00 Cr112.00 Cr130.00 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 1.00 Cr-3.00 Cr4.00 Cr-1.00 Cr14.00 Cr6.00 Cr27.00 Cr61.00 Cr41.00 Cr43.00 Cr53.00 Cr17.00 Cr
Investing Cash Flow -1.00 Cr-2.00 Cr-7.00 Cr-6.00 Cr-12.00 Cr-18.00 Cr-23.00 Cr-63.00 Cr-48.00 Cr-26.00 Cr-29.00 Cr-35.00 Cr
Financing Cash Flow 1.00 Cr6.00 Cr5.00 Cr5.00 Cr-2.00 Cr12.00 Cr1.00 Cr6.00 Cr1.00 Cr-17.00 Cr-14.00 Cr7.00 Cr
Capital Expenditure -1.00 Cr-2.00 Cr-6.00 Cr-6.00 Cr-12.00 Cr-18.00 Cr-24.00 Cr-56.00 Cr-45.00 Cr-26.00 Cr-25.00 Cr-46.00 Cr
Free Cash Flow -0-5.00 Cr-2.00 Cr-7.00 Cr2.00 Cr-12.00 Cr3.00 Cr5.00 Cr-4.00 Cr17.00 Cr28.00 Cr-29.00 Cr
Net Change in Cash 1.00 Cr02.00 Cr-1.00 Cr-004.00 Cr3.00 Cr-6.00 Cr-1.00 Cr10.00 Cr-11.00 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ------------
Operating Margin % 3.8%4.1%6.1%6.6%7.8%7.2%8.8%35.3%18.3%15.0%16.8%19.5%
Net Margin % 1.9%1.4%3.1%2.9%4.8%5.8%5.7%26.3%7.6%7.8%10.8%13.3%
ROE % 5.3%4.5%12.0%13.8%21.6%17.4%24.6%66.3%9.5%10.7%15.2%20.2%
ROCE % ------------

Shareholding Pattern

Insiders
77.49%
Institutions
0.00%
Public Float
0.01%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for KPL

Google News Sat, 17 Oct 2026

Kwality Pharmaceuticals Limited (KPL.NS) interactive stock chart - Yahoo Finance UK

<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE1lSTdQTWdkVjBybVN1YXNrb0VCYUVBdi1LWWdadlZTbWFSaW9VVjhKRWlkOUIzaUJiTjRjZGVyQ25CampkQ1plUmE3c2xxYmhocnBCRHd5SFVKbGxQ?oc=5" target="_blank">Kwality Pharmaceuticals Limited (KPL.NS) in…

Google News Mon, 20 Apr 2026

KPL Stock Price and Chart — NSE:KPL - TradingView

<a href="https://news.google.com/rss/articles/CBMiV0FVX3lxTE5lc0dkbHhiLXdLRXJfc3daY1AxVEVHNnk2ZlNhazFFNFBtb09hTDdQdDRJVGRZX2IxVmYtbkppTXFxeWJMNHotejE0Ni1uZklBV21XUG9tcw?oc=5" target="_blank">KPL Stock Price and Chart — NSE:KPL</a>&nbsp;&nbs…

Google News Sat, 24 Jan 2026

Kiniksa Stock: Arcalyst Is The Engine, But KPL-387 Is The Accelerator (NASDAQ:KNSA) - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNQkpPMG9Ta0tLZi1KcXg0cWtoNERlM2Y3WWl6TXFnNU9leXFkbUp2cXFNbldtV1VlNnBBTHNmMkV2enctTkItMXNQNldSLXBvVWw4SHNoUl9TOGd6bnFHakhyZ3RsYTRKdjlBVmVUMDRjVWc1bTlRRGtLUTN4bVNYcUlWN3djUG5OTnVmak…

Google News Fri, 26 Jun 2026

Here's Why You Should Add Kiniksa Stock to Your Portfolio Now - TradingView

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPcWZYcHplZDI4czZ1X3RrNkxzRXRnRXl1b1MwSUJjTGJpY2Y0eDg3N2xhVTAtZXdORGIteGFtVHUyOFpUcERmd29GSm1hbUU4bmxvUWFaeFlrVU1MUk9PUHJtQ0J2NHBFSnRyMTJ4VjZwdFpfUGJtbm93UjdaMUZNd3NoaGlLQWh0OS1zQ1…

Google News Wed, 27 May 2026

We Think That There Are Issues Underlying Kwality Pharmaceuticals' (NSE:KPL) Earnings - Simply Wall Street

<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxObHd5X2pSOUlPeFoxTzFKWUVnMnJmOS1sSzhCNHdFVUpHRk1mNVN3NU9SejNCWVEzVy13c0ZXNTlKMk9wWnhJbElkOXlhTEc2bjAwS0VHbGY2bXA0NkpJcTQ4YlpQVnZzTHI1V2dJNWtBUFp3Ykk4ZXdjYmpmd1RfdTczcUFORGlPT0Npb2…

Google News Wed, 30 Sep 2026

Kwality Pharmaceuticals (KPL.NS) Holds Firm Near ₹3,632 as Bulls Defend Key Support - Gamma Squeeze - https://www.siam.in/

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPa2pmUmZFenVCY25zQmVhbFd4eml4enp6dDNkMk5pUlBFWkxwYnJpQlh4REdhUmtZb3BRalpvVEVzM1VmMGI0V0ZUVGszNXRob3h5LWVPQzZEN1N0NnlZNS14T09SbmNoN0tLVW9qTEc4eU1Cdno1Z0k1QmZTdmtqTHF5YzRqWThqTnFITV…

KPL — Frequently Asked Questions

What is the current share price of Kwality Pharmaceuticals Limited (KPL)?

As of 2026-10-24 04:55 IST, Kwality Pharmaceuticals Limited (KPL) trades at ₹3,618.30 on NSE. Its 52-week range is ₹1,579.55 to ₹3,844.90.

What is the P/E ratio of KPL?

KPL trades at a trailing price-to-earnings (P/E) ratio of 46.33. The industry average P/E is 35.90. Its price-to-book (P/B) ratio is 11.15.

What is the return on equity (ROE) of KPL?

KPL has a return on equity (ROE) of 20.24%.

Is KPL a good stock to buy?

This page provides a data-driven analysis of Kwality Pharmaceuticals Limited (KPL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space